FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions refers to chemical-pharmaceutical industry and medicine and concerns a new liquid dosage form for oral administration for treatment and prevention of influenza and ARVI. Liquid dosage form contains 2-(imidazol-4-yl)ethanamide of pentane dihydroxy-1,5 acid or its pharmaceutically acceptable salt, 1-[2-(1H-imidazol-4-yl)ethyl]piperidine-2,6-dione or a pharmaceutically acceptable salt thereof in effective amounts and pharmaceutically acceptable excipients, wherein the pH of the liquid dosage form ranges from 3 to 8. Also disclosed is a method for treating and/or preventing influenza and ARVI and using a liquid dosage form for treating and/or preventing influenza and ARVI.
EFFECT: group of inventions provides a stable liquid form of 2-(imidazol-4-yl)ethanamide pentane-dioic-1,5 acid for treating and preventing influenza and ARVI.
17 cl, 33 tbl, 6 ex
